Shots:

• The P-III ORIENT-11 study evaluates the efficacy & safety of sintilimab (200mg) + pemetrexed and platinum CT vs PBO + CT in 397 patients in a ratio (2:1) as 1L treatment for advanced or metastatic nonsq. NSCLC without sensitizing EGFR mutations or ALK rearrangements
• The results demonstrated an OS benefit with a median follow-up of 22.9mos.- m-OS (not reached vs 16.8mos.). Additionally- biomarker results provide insights for patients with high MHC class-II expression
• Sintilimab is a PD-1 inhibitor- jointly developed by Eli Lilly & Innovent. Additionally- the regulatory submission is currently under review in China for sintilimab as 2L treatment of sq. NSCLC

| Ref: PR Newswire | Image: Innovent